



The Digital Examiner

www.prostaidcalgary.org

270 April 2022

“Turn your face to the sun and the shadows will fall behind you.”

Maori Proverb

Connect with us:

Information

Phone: 403-455-1916

info@prostaid.org

Brad Sterling

President

president@prostaid.org

Support Groups

Frank Altin

Warriors

faltin@telusplanet.net

Wives, Partners &

Caregivers

info@prostaid.org

Newly Diagnosed

info@prostaid.org

Mailing Address

PROSTAI D Calgary Society

PO Box 72126

RPO Glenmore Landing

Calgary, Alberta

T2V 5H9

Phone: 403-455-1916

To subscribe to The Digital Examiner

info@prostaid.org

PROSTAI D Calgary is self-funded.

[Click here to help us
to continue our
good work by
donating on-line](#)

Next General Meeting:

**Tuesday, April 12th, 2022 @ 7:30 pm
via ZOOM**

**“Demystifying Chronic Pelvic Pain
Syndrome”**

Please RSVP to program.director@prostaid.org




Safa Rahman has been practicing physiotherapy for over 25 years. She is an orthopedic manual therapist with specializations in pelvic health, TMJ dysfunction, and persistent pain syndromes.

She had the privilege of working at the Chronic Pain Center from 2004-2017, and developed a program specifically for pelvic health and sexuality.

She is a longtime yoga practitioner, a yoga therapist, and on faculty at the Myofascial Yoga Institute. Her presentations at the Institute are conversations with yoga instructors on the impact of pain and trauma on the body, and how to build a relationship with the pelvis as a foundation for movement, awareness and understanding of Self.

She has been the physiotherapist delivering pelvic health education at Prostate Cancer Centre for just over a year, and has pursued further formalized education in treating this population.



Side Bar:



***APRIL meeting will still be via ZOOM only. We are waiting for Well Spring to reopen their Carma House.**

- Please note that I will be away from April 9th to April 18th, with no access to email. After April 8th, to RSVP for the meeting, please use president@prostaid.org.

- * We are starting to look at events and fund raising for this year which includes Wild Wednesdays. If you are interested in volunteering for even ONE Wednesday evening, please let me know.
- * Watch for an email or letter in the mail from PROSTAI D Calgary Society regarding updating our membership list. By replying you will be automatically entered to **WIN** a door prize of a Dinner for Two at the Ranchman's Club.
- * Page 4 includes details regarding participation in a research study by Dr. Colleen Cuthbert.
- * As always, if you have topic suggestions for future meetings, please let me know.

Stay healthy,
Dorothy
Dorothy Rodehutsors
Program Director

What's new in RESEARCH:

What's new generally:

Breaking News: First-in-Class Radioligand Therapy Approved for Advanced Prostate Cancer

- * Today, a new treatment known as 177lutetium-PSMA-617 (Lu-PSMA; trade name Pluvitco™) was approved by the FDA for certain patients with advanced prostate cancer. This medicine delivers a small dose of radiation attached to a molecule that specifically binds to prostate cancer cells. It has been shown to help patients with advanced prostate cancer live longer and maintain quality of life.
- * March 2022

The Next Wave of Novel Radiopharmaceuticals (Video)

- * Alicia Morgans is joined by Shahneen Sandhu to discuss her presentation at GU ASCO 2022 on targeting prostate-specific membrane antigen (PSMA), specifically lutetium, and the next wave of novel radiopharmaceuticals. Dr. Sandhu's presentation focused on where we go with PSMA treatments in the future.
- * March 2022

A Randomized, Controlled, Phase 3 Study of Darolutamide in Addition to ADT Versus ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer (ARANOTE)

- * Trials in Progress Poster Session A focussed on ongoing trials that will contribute to the care of patients with prostate cancer moving forward. Dr. Sharma presented the design of the ARANOTE trial, assessing darolutamide and androgen deprivation therapy (ADT), as compared to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- * February 2022

Appropriate Use Criteria for PSMA PET Imaging

- * Dr. Jadvar discusses the process of developing the AUC for PSMA PET in prostate cancer and reviews 11 clinical scenarios that may be encountered by ordering professionals when they want to consult the AUC for ordering their imaging.
- * March 2022

Prospective quality of life in men choosing open vs. robotic radical prostatectomy: long-term results from a racially diverse multi-institutional database.

- * To compare 5-year health-related quality of life (HRQoL) outcomes between prostate cancer (CaP) patients who underwent robotic-assisted laparoscopic radical prostatectomy (RALP) versus open radical retropubic prostatectomy (RRP) and assess for racial disparities between Caucasian American (CA) and African American (AA) men undergoing surgery.
- * March 2022

ASCO GU 2022: Systemic Therapy for the Management of Rare Prostate Cancer Variants

- * The 2022 GU ASCO Annual meeting included a session on the management of rare variants in genitourinary cancers and a presentation by Dr. Eric Small discussing the role of systemic therapy for the management of rare prostate cancer variants.
- * February 2022

Lifestyle Interventions to Reduce Prostate Cancer Risk (Video)

- * Dr. Mucci provides an overview of the impact of lifestyle and nutrition on cancer and disease risk. She highlights specific types of dietary patterns that are associated with a lower risk of cancer overall, specifically more aggressive forms of prostate cancer or cancers that ultimately will become fatal.
- * December 2021

Supportive care needs of men with prostate cancer: A systematic review update

- * While demonstrating some overarching needs common to most patients with prostate cancer, this review offers novel insight into the unique experiences and needs of men of different demographic backgrounds, which will enable clinicians to deliver individually tailored supportive care
- * January 2022

Articles of Interest:

For Newly Diagnosed:

Understanding What Matters to mCRPC Patients When Considering Treatment Options: A US Survey

- * Nine new treatments for mCRPC, each varying in efficacy and safety, have been approved over the last 10 years, changing the landscape of patient management. Understanding how patients perceive and value the efficacy, safety, and administration burden of these treatments can facilitate shared-decision making to determine optimal management.
- * February 2022

Active Surveillance for Patients with Intermediate-Risk Disease: Risk Versus Benefit

- * Dr. Stacy Loeb presented an overview of active surveillance (AS) for men with localized intermediate-risk prostate cancer. Her talk focused on patient selection, monitoring protocols, outcomes, and future directions.
- * February 2022

Implications of Postponing Cancer Treatment During the Pandemic

- * Dr. Klaassen began his talk by highlighting the heavy demand for resources during the current pandemic, which has been further exacerbated by a limited health system capacity leading to overwhelmed hospitals. Furthermore, medical governing bodies have recommended re-prioritizing surgical cases, attempting to balance the risks of potential increased COVID-19 infections with those of delayed surgery.
- * March 2022

Everyone:

Overall Survival With Darolutamide Versus Placebo in Combination With Docetaxel and Androgen-Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in the Phase 3 ARASENS Trial

- * ARASENS is a randomized phase 3 trial of darolutamide versus placebo in combination with docetaxel and androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is a highly potent androgen receptor (AR) inhibitor with low blood-brain barrier penetration and limited drug-drug interactions.
- * February 2022

Hereditary Cancer Risk Assessment in the Community Urology Practice Setting

- * Precision oncology is the increasing standard of care, both in the somatic and germline compartment, including in prostate cancer clinical practice. Professional guidelines recommend screening for hereditary cancer risk in men with prostate cancer to both inform risk of primary and subsequent cancers, as well as to influence treatment decisions (i.e. PARP inhibitors).
- * February 2022

Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 (Video)

- * Dr. Sartor discusses the phase 3 ARASENS trial, the phase 3 MAGNITUDE study, and the phase 3 PROpel trial.
- * March 2022

EVENT/Research Studies:

Share your views on how oncology treatment decisions are made



The goal of this study is to talk with cancer patients and family caregivers to understand their opinions on how cancer treatment decisions are made.



WHO IS ELIGIBLE?

Must be 18 years of age or older with a cancer diagnosis OR a caregiver 18 years of age or older to an adult patient with a cancer diagnosis.
Must be able to speak and read English and capable of providing informed consent.

WHAT IS INVOLVED?

You will be asked to participate in an online focus group (approximately 90 minutes) to share your thoughts and experiences regarding how oncology treatment decisions are made.

WHAT IS THE GOAL?

Your responses will be used to understand factors related to decision making around value assessment frameworks in oncology treatment decisions making. Using this information, we can help develop healthy policies with patient centered goals at the forefront.

Please reach out to our study team to sign up for a focus group!

Dr Colleen Cuthbert, NP, PhD

cacuthbe@ucalgary.ca

403-220-6198

*Taking part in this study is voluntary, you may quit the survey at any time.

*Every effort will be made to ensure information is kept anonymous and confidential

*This study has received ethics approval from the Health Research Ethics Board of Alberta HREBA.CC-21-0290



PROSTAIID Calgary On-Line



Thank you to our Sponsors and Community Partners

